Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 9/20 | 0.52 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.42 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.41 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12977930 | 0.92 | NAMPT (0.43) | CCR1NAMPTSRD5A1P2RY12POLB | |
| SCHEMBL2773777 | 0.91 | NAMPT (0.43) | CCR1NAMPTSRD5A1P2RY12POLB | |
| SCHEMBL2776483 | 0.89 | CCR1 (0.42) | CCR1NAMPTP2RY12CNR1 | |
| SCHEMBL2774038 | 0.89 | HRH3 (0.45) | CCR1NAMPTEPHX2SRD5A1P2RY12 | |
| SCHEMBL2774059 | 0.89 | P2RY12 (0.45) | CCR1NAMPTEPHX2SRD5A1P2RY12 | |
| SCHEMBL2775515 | 0.88 | EPHX2 (0.44) | CCR1NAMPTEPHX2SRD5A1CNR1 | |
| SCHEMBL2777503 | 0.88 | CCR1 (0.47) | CCR1NAMPT | |
| SCHEMBL2774809 | 0.87 | CCR1 (0.52) | CCR1 | |
| SCHEMBL2776371 | 0.86 | CCR1 (0.46) | CCR1NAMPTEPHX2SRD5A1CNR1 | |
| SCHEMBL2780074 | 0.86 | CCR1 (0.52) | CCR1NAMPTEPHX2SRD5A1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053933-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-03 | — | — | US | claimed |
| EP-2258697-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2010-12-08 | — | — | EP | claimed |
| US-20110053933-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-03 | — | — | US | disclosed |
| EP-2258697-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2010-12-08 | — | — | EP | disclosed |
| EP-2258697-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2010-12-08 | — | — | EP | disclosed |
| WO-2009119537-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | 第一三共株式会社 (JP) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053933-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | F12, F2, C3AR1 | CCR1 1428/4885NAMPT 1696/4885EPHX2 1544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.